Author Information
Gabriel Lopez-Berestein is affiliated with the Department of Cancer Biology and the Department of Experimental Therapeutics at The University of Texas MD Anderson Cancer Center in Houston, TX, USA. Additionally, he is associated with the Center for RNA Interference and Non-Coding RNA at the same institution. His research primarily focuses on cancer biology and the development of experimental therapeutics.Research Contributions
Gabriel Lopez-Berestein has made significant contributions to the field of cancer research, with a particular focus on understanding and combating various forms of cancer through innovative therapeutic strategies. His work includes key studies on tamoxifen resistance in ER+ breast cancer, the role of endothelial p130cas in resistance to anti-angiogenesis therapy, and the use of noncoding RNAs to enhance the efficacy of chemotherapy. His research also delves into the application of artificial intelligence in understanding tumor microenvironments, the impact of chronic stress on tumor growth and angiogenesis, and the potential of ncRNA therapy in treating triple-negative breast cancer.Aliases
Gabriel Lopez-Berestein is also known by several aliases, including G. Lopez-Berestein, G Lopez-Berestein, G. Lopez‐berestein, Gabriel López-berestein, Gabriel Lopez‐berestein, Gabe Lopez-Berestein, and Gabriel Lopez-berestein.Publication and Citation Metrics
| Metric |
Value |
| Citation Count |
37,740 |
| h-index |
95 |
| Paper Count |
629 |
